Clinical Trial 23571

• Overview

  Study Title:

  The MIND-BC Study: MIND Diet for Breast Cancer Cognition

  Objective:

  Aim 1: To evaluate the efficacy of the MIND diet in reducing self-reported cancer-related cognitive impairment (primary outcome) in early-stage breast cancer survivors. Aim 2: To evaluate the efficacy of the MIND diet in improving objective cancer-related cognitive impairment (i.e., best objective performance and usual objective performance), fatigue, mood, and QOL (secondary outcomes) in early-stage breast cancer survivors. Exploratory Aim 3: To explore putative mechanisms of improvements in cognition secondary to the MIND diet (inflammatory biomarkers, body composition, nutrient biomarkers, etc.) versus controls.

• Inclusion Criteria

  Key Inclusion Criteria:
  • Previously diagnosed with stage I-III breast cancer.
  • Able to speak and read English.
  • Able to consume foods orally.
  • >18 years of age.
  • Able to provide informed consent.
  • Have no documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., schizophrenia).
  • Report 'somewhat' to 'very much' cognitive impairment in the past week (i.e., a score ≥ 3 on a 1-5 scale) that they attribute to cancer or its treatment.
  • Report a MIND diet score > Willing to consume the MIND diet.
  • Completed adjuvant treatment 6 months to three years previously.

• Exclusion Criteria

  Key Exclusion Criteria:
  • Not meeting all of the inclusion criteria.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.